Altamira Therapeutics .(CYTO) - 2020 Q4 - Annual Report

Financial Performance - Net loss for H2 2020 was CHF 5.5 million, or CHF 0.75 per share, compared to CHF 3.0 million, or CHF 0.83 per share, for H2 2019[14]. - Net loss attributable to owners for 2020 was CHF 8.2 million, or CHF 1.36 per share, compared to CHF 6.6 million, or CHF 2.28 per share, for 2019[18]. - Net loss attributable to owners of the Company for the twelve months ended December 31, 2020, was CHF 8,200,165, compared to CHF 6,631,901 in 2019, indicating an increase of approximately 23.7%[26]. - Basic and diluted loss per share for the twelve months ended December 31, 2020, was CHF (1.36), compared to CHF (2.28) in 2019, showing an improvement of approximately 40.4%[26]. Operating Expenses - Total operating expenses for H2 2020 were CHF 2.9 million, a decrease from CHF 3.2 million in H2 2019[13]. - Total operating expenses for 2020 were CHF 5.3 million, down from CHF 7.3 million in 2019[16]. - Total operating loss for the six months ended December 31, 2020, was CHF 2,862,459, a decrease from CHF 3,151,586 in the same period of 2019, representing a reduction of approximately 9%[26]. - Research and development expenses decreased to CHF 1,978,232 for the six months ended December 31, 2020, compared to CHF 2,020,990 in 2019, reflecting a decline of about 2%[26]. Cash and Assets - Cash and cash equivalents at December 31, 2020, totaled CHF 11.3 million[15]. - Cash and cash equivalents rose to CHF 11,258,870 in 2020, up from CHF 1,384,720 in 2019, representing an increase of approximately 713%[28]. - Total assets increased significantly to CHF 20,799,367 in 2020 from CHF 9,226,151 in 2019, marking an increase of about 125%[28]. Liabilities - Total liabilities increased to CHF 4,029,477 in 2020 from CHF 3,190,018 in 2019, reflecting an increase of about 26%[28]. Shareholder Information - Auris Medical raised CHF 16.6 million in equity through share placements and warrant exercises[11]. - The average weighted number of shares outstanding increased to 7,432,839 in the six months ended December 31, 2020, compared to 3,628,614 in the same period of 2019, an increase of approximately 105%[26]. Future Outlook - Auris Medical expects to launch AM-301 nasal spray in selected markets towards the end of Q2 2021[2]. - The Phase 2 trial for AM-125 in acute vertigo is expected to complete enrollment in Q3 2021[2]. - The company anticipates total cash needs in 2021 to be between CHF 11.5 to 13 million[21]. - A strategy review is ongoing to explore potential strategic alternatives to maximize shareholder value[12]. Other Financial Metrics - Interest income for the six months ended December 31, 2020, was CHF 258, a significant decrease from CHF 17,882 in 2019, indicating a decline of about 98.6%[26]. - The Company reported a foreign currency exchange loss of CHF 303,531 for the six months ended December 31, 2020, compared to a gain of CHF 44,548 in 2019[26].